BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bayraktar Y, Harmanci O, Büyükasik Y, Shorbagi AI, Sungur AH, Boylu CA, Gürgey A, Balkanci F. JAK2V617F mutation in patients with portal vein thrombosis. Dig Dis Sci 2008;53:2778-83. [PMID: 18343999 DOI: 10.1007/s10620-008-0225-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Xavier SG, Gadelha T, Rezende SM, Zalcberg IR, Spector N. JAK2V617F mutation in patients with thrombosis: to screen or not to screen?: SCREENING OF JAK2V617F MUTATION IN THROMBOSIS. International Journal of Laboratory Hematology 2011;33:117-24. [DOI: 10.1111/j.1751-553x.2010.01275.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
2 Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, Grandi AM, Ageno W. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009;113:5617-23. [PMID: 19273837 DOI: 10.1182/blood-2008-12-196014] [Cited by in Crossref: 115] [Cited by in F6Publishing: 110] [Article Influence: 9.6] [Reference Citation Analysis]
3 Ventura P, Venturelli G, Marcacci M, Fiorini M, Marchini S, Cuoghi C, Pietrangelo A. Hyperhomocysteinemia and MTHFR C677T polymorphism in patients with portal vein thrombosis complicating liver cirrhosis. Thromb Res. 2016;141:189-195. [PMID: 27065203 DOI: 10.1016/j.thromres.2016.03.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
4 Kanellopoulou T, Alexopoulou A, Koskinas J. JAK2V617F mutation is ubiquitously present in splanchnic vein thrombosis accompanying myeloproliferative syndromes: Letters to the Editors. Alimentary Pharmacology & Therapeutics 2011;33:1382-3. [DOI: 10.1111/j.1365-2036.2011.04670.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Orr DW, Patel RK, Lea NC, Westbrook RH, O'Grady JG, Heaton ND, Pagliuca A, Mufti GJ, Heneghan MA. The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis. Aliment Pharmacol Ther 2010;31:1330-6. [PMID: 20331577 DOI: 10.1111/j.1365-2036.2010.04299.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
6 Xavier SG, Gadelha T, Pimenta G, Eugenio AM, Ribeiro DD, Gomes FM, Bonamino M, Zalcberg IR, Spector N. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci. 2010;55:1770-1777. [PMID: 19690956 DOI: 10.1007/s10620-009-0933-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
7 Qi X, Yang Z, Bai M, Shi X, Han G, Fan D. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis: Meta-analysis: JAK2V617F mutation in BCS and PVST. Alimentary Pharmacology & Therapeutics 2011;33:1087-103. [DOI: 10.1111/j.1365-2036.2011.04627.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
8 Casini A, Fontana P, Lecompte T. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. J Thromb Haemost 2013;11:1215-27. [DOI: 10.1111/jth.12265] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
9 Alghasham N, Alnouri Y, Abalkhail H, Khalil S. Detection of mutations in JAK2 exons 12-15 by Sanger sequencing. Int Jnl Lab Hem 2016;38:34-41. [DOI: 10.1111/ijlh.12425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
10 Moussaoui S, Saussoy P, Ambroise J, Defour JP, Zouitene R, Sifi K, Abadi N. Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population. Clin Appl Thromb Hemost 2017;23:105-15. [DOI: 10.1177/1076029615600789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Karam D, Iyer V, Agrawal B. Occult myeloproliferative neoplasms: not so occult any more. BMJ Case Rep 2017;2017:bcr-2017-219388. [PMID: 28559287 DOI: 10.1136/bcr-2017-219388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Morag I, Shah PS, Epelman M, Daneman A, Strauss T, Moore AM. Childhood outcomes of neonates diagnosed with portal vein thrombosis. J Paediatr Child Health 2011;47:356-60. [PMID: 21309882 DOI: 10.1111/j.1440-1754.2010.01987.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
13 Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921-4928. [PMID: 23043069 DOI: 10.1182/blood-2011-09-376517] [Cited by in Crossref: 194] [Cited by in F6Publishing: 150] [Article Influence: 21.6] [Reference Citation Analysis]
14 Lamy M, Palazzo P, Agius P, Chomel JC, Ciron J, Berthomet A, Cantagrel P, Prigent J, Ingrand P, Puyade M, Neau JP. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis? Cerebrovasc Dis 2017;44:97-104. [PMID: 28609766 DOI: 10.1159/000471891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Saugel B, Lee M, Feichtinger S, Hapfelmeier A, Schmid RM, Siveke JT. Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis. J Thromb Thrombolysis. 2015;40:54-60. [PMID: 25115839 DOI: 10.1007/s11239-014-1124-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
16 Shetty S, Ghosh K. Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosis – A concise review. Thrombosis Research 2011;127:505-12. [DOI: 10.1016/j.thromres.2010.09.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
17 Gianelli U, Iurlo A, Cattaneo D, Bossi A, Cortinovis I, Augello C, Moro A, Savi F, Castelli R, Brambilla C, Bianchi P, Primignani M, Cortelezzi A, Bosari S. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. Leuk Res 2015;39:525-9. [PMID: 25840747 DOI: 10.1016/j.leukres.2015.03.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]